Swiss online pharmacy DocMorris hikes 2026 guidance after strong Q3 earnings

Swiss online pharmacy DocMorris has increased its revenue and profit forecasts for 2026 following a strong third-quarter performance. In the Q3, the company's prescription drug sales surged, leading to breakeven on an adjusted EBITDA basis, ahead of the planned fourth quarter. DocMorris now anticipates a 12.5% to 15% growth in external revenue for 2026, up from the previous range of 9% to 13%.

Adjusted EBITDA is expected to be better than a loss of 10 million Swiss francs, contrasting with the prior guidance of a loss between 10 million and 17.5 million francs.

In the third quarter, DocMorris' external revenue, which includes the online revenue of partner pharmacies, surged by 21.4% to 342.7 million francs. Revenue grew 22.1% to 327.4 million francs. The company attributed the growth to prescription medicines in Germany, its main market, where external revenue rose 78.3% year-on-year to 108.1 million francs, a 33.5% increase from the second quarter.

Non-prescription sales grew 5.5% to 218.2 million francs. Over-the-counter sales remained steady at 3.5% growth. Digital services, comprising the TeleClinic telemedicine platform, retail media, and marketplace, experienced a significant 46.1% growth, reaching 13.9 million francs.

The company currently has 13.1 million active customers, an increase of 1.5 million compared to the previous year. DocMorris has reaffirmed its target of reaching free cash flow breakeven by 2027 and maintained its capital expenditure target at below 30 million francs for 2026.